



# Correction: Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial

Søren Gullaksen<sup>1,2,3</sup> · Liv Vernstrøm<sup>1,2</sup> · Steffen S. Sørensen<sup>1,2</sup> · Steffen Ringgaard<sup>4</sup> · Christoffer Laustsen<sup>4</sup> · Kristian L. Funck<sup>3</sup> · Per L. Poulsen<sup>1,3</sup> · Esben Laugesen<sup>2,3,5</sup>

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024

**Correction: Diabetologia (2023) 66:813-825**  
<https://doi.org/10.1007/s00125-023-05876-w>

In Table 1 showing the baseline characteristics by treatment group, the entries for BMI, previous history of CVD and GFR were incorrect due to calculation errors. The original article has been corrected.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

The original article can be found online at <https://doi.org/10.1007/s00125-023-05876-w>.

---

✉ Søren Gullaksen  
soegul@clin.au.dk

- <sup>1</sup> Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
- <sup>2</sup> Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark
- <sup>3</sup> Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark
- <sup>4</sup> Department of Clinical Medicine, The MR Research Centre, Aarhus University, Aarhus, Denmark
- <sup>5</sup> Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark